Open AccessTreprostinil in Advanced Experimental Pulmonary Hypertension: Beneficial Outcome Without Reversed Pulmonary Vascular Remodeling
Author(s) -
Mirjam E. van Albada,
Richard van Veghel,
Adri H. CrommeDijkhuis,
Regien G. Schoemaker,
R Berger
Publication year - 2006
Publication title -
journal of cardiovascular pharmacology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.762
H-Index - 100
eISSN - 1533-4023
pISSN - 0160-2446
DOI - 10.1097/01.fjc.0000248229.87510.9b
Subject(s) - treprostinil , medicine , pulmonary hypertension , cardiology , heart failure , right ventricular hypertrophy , saline , vascular resistance , hemodynamics , ventricle , histopathology , pathology
Beneficial effects of treprostinil, a stable prostacyclin analogue, were demonstrated in patients with pulmonary arterial hypertension (PAH). Although regression of pulmonary vascular remodeling has been suggested as therapeutic mechanism, its mode of action remains unknown.